M&A Corner
Alterity Therapeutics Receives A$4.74M Research & Development Tax Incentive Refund22 Aug 2023
Alterity Therapeutics Ltd (NASDAQ:ATHE) announced a A$4.74 million cash refund from the Australian Taxation Office through the Research and Development... Continue Reading
|
mRNA JV Arcalis Awarded $115m from Japanese Gov22 Aug 2023
Arcalis, a mRNA-focused contract development manufacturing organization (CDMO), is a joint venture between Arcturus Therapeutics and Japan’s Axcelead. Arcturus holds... Continue Reading
|
Visana Health Raises $10.1M for Virtual Women’s Health Clinic22 Aug 2023
Visana Health, a virtual-first women’s health clinic, has raised $10.1M in seed funding, co-led by Flare Capital Partners and Frist... Continue Reading
|
Dolbey, SOAP Health Partner on AI-Driven Early Disease Detection22 Aug 2023
Dolbey and Company, Inc. have forged a strategic alliance with leading AI medical innovator SOAP Health. This union merges Dolbey’s... Continue Reading
|
CareFirst BlueCross BlueShield, Ryse Health Partner to Accelerate VBC for Diabetes Patients22 Aug 2023
CareFirst BlueCross BlueShield and Ryse Health have unveiled a groundbreaking partnership to enhance diabetes care. As the largest nonprofit health... Continue Reading
|
Satio Partners with BARDA DRIVe to Develop a Novel Patch-Based Ebolavirus Diagnostic22 Aug 2023
Satio has secured a contract from BARDA, a division of the U.S. Department of Health and Human Services, to create... Continue Reading
|
AliveCor and Clario Partner to Offer Decentralized Clinical Trials- Focused Six-Lead ECG Solutions22 Aug 2023
Clario’s expanded collaboration with AliveCor introduces enhanced medical-grade six-lead ECG data collection through the KardiaRx app, benefiting trial participants. This... Continue Reading
|
CervoMed Announces Completion of Merger with EIP Pharma22 Aug 2023
CervoMed Inc., a clinical-stage company formed through a merger with EIP Pharma, is focused on advancing the oral stress kinase... Continue Reading
|
Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout22 Aug 2023
Harmony Biosciences has announced its intention to acquire Zynerba Pharmaceuticals to bolster its portfolio in rare neuropsychiatric disorders. The deal... Continue Reading
|
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma22 Aug 2023
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) has gained stockholder approval for key measures at a recent special meeting. The approvals include... Continue Reading
|